Israel's Teva and development partner H. Lundbeck say they have halted work on an oral Copaxone for multiple sclerosis. Trials conducted from 2000 to 2004 did not deliver results as significant as the injectable version of Copaxone (glatiramer acetate). Copaxone sales crested over a billion dollars last year, making it Teva's most lucrative drug.
- here's the article from Globes